European Registry of Next Generation Imaging in Advanced Prostate Cancer (RING): protocol for an international, prospective registry study.
Daria Chernysheva, Stefano Fanti, Anders Bjartell...
https://pubmed.ncbi.nlm.nih.gov/41338644Actively Recruiting
Age: 18Years +
MALE
ID06866782
European Registry of Next Generation Imaging in Advanced Prostate Cancer
Led by Fundacio Puigvert · Updated on 2025-03-11
600
Participants Needed
24
Research Sites
52 weeks
Total Duration
On this page
Sponsors
F
Fundacio Puigvert
Lead Sponsor
E
European Association of Urology Research Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are collecting real-world data on advanced prostate cancer to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. This study focuses on men aged 18 or older with confirmed prostate cancer who need imaging to assess possible metastases either at diagnosis or after relapse. It aims to understand when NGI should be used, how it influences treatment decisions, and its impact on patient outcomes. Participants will receive standard care without experimental treatments. Imaging will be done using either conventional methods, NGI, or both, according to local clinical practice and guidelines. The study includes a cross-sectional observation to evaluate imaging benefits and a longitudinal observation to assess survival outcomes and treatment response based on the imaging approach used. During the study, data will be collected from medical records including patient demographics, medical history, tumor characteristics, and imaging results. Researchers will track the proportion of patients requiring each imaging type and changes in treatment prompted by imaging results within 4 to 6 weeks. The study involves no additional procedures beyond routine care, and participation will continue until the study end in December 2026.
CONDITIONS
Brief Title
European Registry of Next Generation Imaging in Advanced Prostate Cancer
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
- Adult male patients aged 18 years or older with no upper age limit
- Histologically confirmed prostate cancer
- Patients requiring imaging exploration (conventional, next-generation imaging, or both) at high risk for metastatic deposits at the hormone-sensitive stage, either at diagnosis or at biochemical relapse/progression after local treatment
- Patients who have signed a written informed consent form
You will not qualify if you...
- Participation in other studies requiring next-generation imaging as a triage test for metastatic assessment
- Presence of any other clinically significant disease or condition that discourages participation, as judged by the investigator
- Inability to complete the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - 4 to 6 weeks
Participants undergo imaging exploration using conventional imaging, next generation imaging, or both to assess metastatic prostate cancer.
1 to 2 imaging visits depending on imaging modality
Long-term Monitoring
Duration - Up to several years
Participants are observed over time to evaluate survival outcomes and disease progression in relation to the imaging pathway undertaken.
Trial Site Locations
Total: 24 locations
1
Universitair Ziekenhuis Leuven
Leuven, Belgium
Not Yet Recruiting
2
Hospital Center University De Lille
Lille, France
Not Yet Recruiting
3
Hospices Civils de Lyon
Lyon, France
Not Yet Recruiting
4
University Hospitals Pitié Salpêtrière
Paris, France
Not Yet Recruiting
5
Bonn University Hospital
Bonn, Germany
Not Yet Recruiting
6
Martini Klinik
Hamburg, Germany
Not Yet Recruiting
7
München LMU L MU-University Clinic
Munich, Germany
Not Yet Recruiting
8
Urologische Klinik München - Planegg
Planegg, Germany
Not Yet Recruiting
9
Universitätsklinik Tübingen
Tübingen, Germany
Not Yet Recruiting
10
IRCCS Universit of Bologna
Bologna, Italy
Not Yet Recruiting
11
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
Actively Recruiting
12
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
Not Yet Recruiting
13
IRCCS Ospedale San Raffaele
Milan, Italy
Not Yet Recruiting
14
ERASMUS MC & Franciscus Hospital
Rotterdam, Netherlands
Not Yet Recruiting
15
Uniwersytet Jagielloński Collegium Medicum
Krakow, Poland
Not Yet Recruiting
16
Fundació Puigvert
Barcelona, Spain
Actively Recruiting
17
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Actively Recruiting
18
Hospital Universitario Reina Sofia
Córdoba, Spain
Not Yet Recruiting
19
Hospital Universitario La Paz
Madrid, Spain
Not Yet Recruiting
20
Hospital Universitario Ramón y Cajal
Madrid, Spain
Not Yet Recruiting
21
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Spain
Actively Recruiting
22
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Not Yet Recruiting
23
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain
Not Yet Recruiting
24
Skånes universitetssjukhus Malmö
Malmö, Sweden
Not Yet Recruiting
Loading map...
Research Team
F
Francesco Sanguedolce, MD, PhD
D
Daria Chernysheva, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here